CTRI/2012/08/002926招募中4 期
An open-label, randomized, active-controlled, parallel-arm, single-center study on effect of sitagliptin on T2DM patients on treatment with metformin and insulin. - SWIM
Jothydevs Diabetes and Research Center0 个研究点目标入组 440 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 440
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •T2DM patients on metformin and biphasic or basal regimens of insulin
- •HbA1c >=7.3% to <=8.5%
- •Age: 25 to 60 yrs
- •Insulin TDD > 10 IU
排除标准
- •History of type 1 diabetes mellitus
- •History of pancreatitis
- •Creatinine clearance <=50 mL/min
- •Chronic liver & kidney diseases, SGOT/PT>=2.5x upper limit of normal, uncontrolled thyroid disorders, cardiac failure, hemochromatosis, autoimmune disorders, and corticosteroid intake.
- •BMI >40 kg/m2
- •Use of acarbose, pioglitazone or short-acting insulin analogues at time of run-in phase
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of two different aflibercept regimens in subjects with nAMD.eovascular Age-Related Macular Degeneration (nAMD)MedDRA version: 18.0Level: PTClassification code 10071129Term: Neovascular age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 18.0Level: SOCClassification code 10015919Term: Eye disordersSystem Organ Class: 10015919 - Eye disordersEUCTR2013-000120-33-ESBayer HealthCare AG335
进行中（未招募）
1 期
Efficacy and safety of three different aflibercept regimens in subjects with DME.Diabetic macular edema (DME)MedDRA version: 20.1Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.0Level: SOCClassification code 10015919Term: Eye disordersSystem Organ Class: 10015919 - Eye disordersEUCTR2014-004938-25-DEBayer AG490
进行中（未招募）
1 期
Efficacy and safety of two different aflibercept regimens in subjects with nAMD.eovascular Age-Related Macular Degeneration(nAMD)MedDRA version: 20.0Level: PTClassification code 10071129Term: Neovascular age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.0Level: SOCClassification code 10015919Term: Eye disordersSystem Organ Class: 10015919 - Eye disordersEUCTR2013-000120-33-PTBayer AG330
进行中（未招募）
1 期
Efficacy and safety of two different aflibercept regimens in subjects with nAMD.eovascular Age-Related Macular Degeneration(nAMD)MedDRA version: 19.0Level: PTClassification code 10071129Term: Neovascular age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 19.0Level: SOCClassification code 10015919Term: Eye disordersSystem Organ Class: 10015919 - Eye disordersEUCTR2013-000120-33-ATBayer AG330
进行中（未招募）
1 期
Efficacy and safety of two different aflibercept regimens in subjects with nAMD.Neovascular Age-Related Macular Degeneration (nAMD)MedDRA version: 20.0 Level: PT Classification code 10071129 Term: Neovascular age-related macular degeneration System Organ Class: 10015919 - Eye disordersMedDRA version: 20.0 Level: SOC Classification code 10015919 Term: Eye disorders System Organ Class: 10015919 - Eye disordersEUCTR2013-000120-33-GBBayer AG330